National Storage Mechanism | Additional information
RNS Number : 2966L
Societe Generale SA
29 April 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

                         Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.0001 ordinary shares

Date of dealing

28/04/2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 


Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

3,313,096

1.01

42,839

0.01

(2) Derivatives (other than options)

0

0.00

3,033,991

0.92

(3) Options and agreements to purchase/sell

58,500

0.02

0

0.00

Total

*9,001,948

*2.73

3,076,830

0.93

                               

* Include the holding of 5,630,352 shares on borrow products

               

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short


Number

(%)

Number

(%)

(1) Relevant securities





(2) Derivatives (other than options)





(3) Options and agreements to purchase/sell





Total





 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

200

187.14

Purchase

100

187.67

Purchase

2

187.98

Purchase

100

187.41

Purchase

100

187.05

Purchase

100

188.64

Purchase

100

186.94

Purchase

100

187.54

Purchase

100

186.99

Purchase

8

187.8

Purchase

1

187.88

Purchase

100

187.39

Purchase

99

187.88

Purchase

100

187.67

Purchase

1

187.3

Purchase

100

187.71

Purchase

100

187.05

Purchase

99

187.3

Purchase

2

187.68

Purchase

100

186.8

Purchase

100

187.99

Purchase

3

187.51

Purchase

3

187.14

Purchase

97

187.14

Purchase

15

187.91

Purchase

34

187.91

Purchase

18

187.91

Purchase

98

186.92

Purchase

2

186.92

Purchase

95

187.51

Purchase

2

187.51

Purchase

4

186.98

Purchase

2

186.98

Purchase

100

187.16

Purchase

100

186.64

Purchase

2

187.72

Purchase

98

187.72

Purchase

2

187.69

Purchase

100

187.67

Purchase

3

188.06

Purchase

100

187.56

Purchase

100

187.59

Purchase

3

187.76

Purchase

50

187.76

Purchase

14

187.74

Purchase

47

187.76

Purchase

86

187.74

Purchase

1

187.72

Purchase

200

187.5575

Purchase

100

187.18

Purchase

100

187.01

Purchase

100

187.65

Purchase

100

187.55

Purchase

1

187.66

Purchase

2

187.66

Purchase

100

187.08

Purchase

100

188.5

Purchase

99

187.76

Purchase

1

187.76

Purchase

96

187.74

Purchase

4

187.74

Purchase

100

187.89

Purchase

27

187.73

Purchase

73

187.73

Purchase

2

188.41

Purchase

10

187.17

Purchase

32

187.334688

Purchase

100

186.79

Purchase

100

187.18

Purchase

100

188.49

Purchase

100

187.73

Purchase

100

187.57

Purchase

100

187.09

Purchase

100

187.03

Purchase

2

188.6

Purchase

27

188.6

Purchase

100

187.73

Purchase

100

186.65

Purchase

100

187.38

Purchase

2

187.28

Purchase

100

187.3

Purchase

98

187.28

Purchase

100

186.94

Purchase

72

187.327639

Purchase

100

187.19

Purchase

100

187.01

Purchase

5

187.39

Purchase

95

187.39

Purchase

100

186.64

Sale

21

189.29

Sale

100

187.27

Sale

100

187.62

Sale

9

187.32

Sale

50

187.82

Sale

100

187.79

Sale

52

187.68

Sale

100

187.4

Sale

100

188

Sale

100

187.68

Sale

100

187.94

Sale

100

187.45

Sale

100

187.68

Sale

98

187.87

Sale

2

187.87

Sale

1

187.98

Sale

99

187.98

Sale

100

187.64

Sale

100

187.62

Sale

23

189.05

Sale

30

188.94

Sale

19

188.84

Sale

100

188.63

Sale

34

188.52

Sale

100

187.48

Sale

10

187.32

Sale

10

187.32

Sale

10

187.32

Sale

60

187.32

Sale

10

187.32

Sale

100

187.62

Sale

20

188.64

Sale

10

188.71

Sale

6

188.77

Sale

100

188.5

Sale

26

188.5

Sale

14

188.59

Sale

13

188.94

Sale

56

188.64

Sale

100

188.62

Sale

113

188.575841

Sale

24

188.67

Sale

100

188.64

Sale

122

189.069836

Sale

50

187.77

Sale

50

187.77

Sale

100

187.27

Sale

9

187.76

Sale

91

187.76

Sale

100

187.27

Sale

100

187.72

Sale

423

188.571513

Sale

55

189.01

Sale

100

189.19

Sale

100

189.3

Sale

16

189.07

Sale

11

189.19

Sale

84

188.88

Sale

16

188.88

Sale

12

188.95

Sale

100

189.26

Sale

240

189.216167

Sale

11

189.1

Sale

89

189.1

Sale

11

189.08

Sale

170

187.35

Sale

8

187.558

Total Purchases

5,939


Total Sales

4,588



 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)





 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)








 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)




 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)





Ap21

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

 

Date of disclosure

29/04/2020

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected


If a connected EFM, state nature of connection (Note 10)


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ap23

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

 

 

Product name,

e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Listed Put Option

Sale

40,000

175

American options

15/01/2021

Listed Put Option

Sale

18,500

190

American options

15/01/2021

 

 

Notes

 

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.          For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKKCBKOBKKNQB